Compare AbCellera Biologics Inc (ABCL) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Occidental Petroleum Corporation — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Occidental Petroleum Corporation trades at $53.57 (market cap $51.40B). The key difference: Occidental Petroleum Corporation is far larger — about 21.9× AbCellera Biologics Inc's market cap, and Occidental Petroleum Corporation pays a 2.01% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OXY | |
|---|---|---|
Market Cap | $2.35B | $51.40B |
Sector | Health | Energy |
52-Week High | $8.12 | $66.24 |
52-Week Low | $2.78 | $38.92 |
Enterprise Value | $1.99B | $72.49B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Occidental Petroleum (OXY) trades at $51.68, up 5.66% with strong recent earnings beats. The stock shows bearish technical signals but attractive valuation with EV/EBITDA of 6.34x. Recent CEO transition and debt reduction efforts are key developments, while oil price volatility remains a primary factor. Analyst consensus leans positive with 48% buy ratings and $66.86 price target suggesting 29% upside potential from current levels.
OXY presents value opportunity with reasonable valuation and consistent earnings outperformance, though exposure to oil prices and execution risks under new leadership warrant caution. The company's pivot toward carbon capture technologies and Permian Basin strength provide long-term growth catalysts, but near-term performance depends on commodity price stability and successful debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
